Engitix Therapeutics
Calum MacLeod has been in the medicinal chemistry industry for over 18 years. Calum began their career in 2003 as a Postdoctoral Research Fellow at Adolor. In 2005, they joined Charles River Laboratories as a Medicinal Chemistry Team Leader, where they have since gained extensive experience in a wide range of therapeutic areas, including CNS, oncology, immunology, antiviral, and antibacterial programmes. In 2018, they moved to Pharmaron as an Associate Director of Medicinal Chemistry, and in 2022, they were appointed Director of Medicinal Chemistry at Engitix Therapeutics. To date, projects worked on have delivered 6 (and counting) preclinical development candidates, including 6 operating as the chemistry team lead.
Calum MacLeod attended the University of Glasgow from 1999 to 2002, where they earned a PhD in Chemistry.
This person is not in any offices
Engitix Therapeutics
To create a healthier future for patients with life-threatening diseases, Engitix Therapeutics is using its pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumors.